Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata et al. · The Lancet Oncology · 2017 · 539 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 529 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday et al. · Molecular Cancer Therapeutics · 2014 · 496 citations

Medicine, Oncology, Pharmacology +16

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Pascal Furet, Vito Guagnano, Robin A. Fairhurst et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 470 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study

Dejan Juric, Jordi Rodón, Josep Tabernero et al. · Journal of Clinical Oncology · 2018 · 439 citations

Medicine, Oncology, Pharmacology +14